Caldera Therapeutics

Founded in 2025, Caldera Therapeutics specializes in advancing treatments for inflammatory diseases.Caldera Therapeutics focuses on developing innovative therapeutic solutions for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases, centering on its flagship product, the bispecific antibody CLD-423. This first-in-class therapeutic targets the clinically validated IL-23p19 and TL1A pathways, combining these two potent autoimmune targets into a single molecule. The primary end use cases for CLD-423 revolve around improving treatment efficacy for patients suffering from IBD, particularly where existing single-target therapies have reached an efficacy ceiling. Currently, the Phase 1 clinical trial of CLD-423 is ongoing, which signifies its recent introduction into the clinical testing phase. Given the nature of the biotechnology sector, revenue generation is expected to primarily occur through partnerships with healthcare organizations and potentially through licensing agreements with pharmaceutical companies upon successful clinical validation of its product. The structure of transactions may involve B2B partnerships with hospitals and healthcare providers who would integrate CLD-423 into their treatment protocols. Pricing for the bispecific antibody is anticipated to be determined in relation to the therapeutic value and outcomes achieved, with no specific pricing plans disclosed at this time.00 mn to advance the clinical development of CLD-423 and explore further therapeutic candidates targeting inflammatory diseases. The company aims to expand its clinical trials and plans to target the North American and European markets for growth by 2026.

1. Series A

   Jan 8, 2026

   Amount

   $38M

   Investors

   Locked

2. Series A

   Apr 1, 2025

   Amount

   $75M

   Investors

   Locked